Merck & Company Inc (MRK)vsQiagen NV (QGEN)
MRK
Merck & Company Inc
$143.93
-0.54%
HEALTHCARE · Cap: $355.10B
QGEN
Qiagen NV
$42.50
+0.88%
HEALTHCARE · Cap: $8.75B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 3069% more annual revenue ($66.57B vs $2.10B). QGEN leads profitability with a 19.5% profit margin vs 4.8%. QGEN appears more attractively valued with a PEG of 1.16. QGEN earns a higher WallStSmart Score of 60/100 (C+).
MRK
Hold36
out of 100
Grade: F
QGEN
Buy60
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.93
$61.09 premium
Margin of Safety
-27.1%
Fair Value
$40.16
Current Price
$42.50
$2.34 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Reasonable price relative to book value
Strong operational efficiency at 26.3%
Areas to Watch
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
0.3% revenue growth
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : QGEN
The strongest argument for QGEN centers on Price/Book, Operating Margin. Profitability is solid with margins at 19.5% and operating margin at 26.3%. PEG of 1.16 suggests the stock is reasonably priced for its growth.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : QGEN
The primary concerns for QGEN are Revenue Growth.
Key Dynamics to Monitor
QGEN carries more volatility with a beta of 0.63 — expect wider price swings.
MRK is growing revenue faster at 5.1% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
QGEN scores higher overall (60/100 vs 36/100), backed by strong 19.5% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Qiagen NV
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
QIAGEN NV provides sample-to-knowledge solutions that transform biological materials into molecular knowledge globally. The company is headquartered in Venlo, the Netherlands.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?